Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23446793 | 0.84 | L3MBTL1 (0.35) | L3MBTL1NOD1KMT2APOLBCTSC | |
| SCHEMBL24966603 | 0.84 | L3MBTL1 (0.35) | L3MBTL1NOD1KMT2APOLBCTSC | |
| SCHEMBL23380920 | 0.82 | FOLH1 (0.46) | CTSC | |
| SCHEMBL1669059 | 0.82 | MAPT (0.39) | L3MBTL1NOD1KMT2APOLBTDP1 | |
| SCHEMBL23792690 | 0.82 | NOD1 (0.34) | L3MBTL1NOD1KMT2APOLBCTSC | |
| SCHEMBL25603577 | 0.81 | L3MBTL1 (0.35) | L3MBTL1NOD1KMT2APOLB | |
| SCHEMBL23685295 | 0.79 | CTSC (0.34) | L3MBTL1NOD1KMT2APOLBCTSC | |
| SCHEMBL18495355 | 0.77 | CTSC (0.33) | L3MBTL1CTSCDNM1 | |
| SCHEMBL24302416 | 0.77 | L3MBTL1 (0.31) | L3MBTL1CTSC | |
| SCHEMBL21516155 | 0.76 | TDP1 (0.36) | L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | L3MBTL1 3479/4885NOD1 939/4885KMT2A 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.